Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483835 | 1.00 | TACR1 (0.77) | TACR1KCNH2OPRL1 | |
| SCHEMBL6484875 | 0.94 | TACR1 (0.75) | TACR1KCNH2OPRL1 | |
| SCHEMBL6484883 | 0.94 | TACR1 (0.75) | TACR1KCNH2OPRL1 | |
| SCHEMBL6498993 | 0.91 | TACR1 (0.72) | TACR1KCNH2OPRL1 | |
| SCHEMBL6491543 | 0.91 | TACR1 (0.77) | TACR1KCNH2 | |
| SCHEMBL7178630 | 0.91 | TACR1 (0.79) | TACR1KCNH2 | |
| SCHEMBL6491549 | 0.91 | TACR1 (0.77) | TACR1KCNH2 | |
| SCHEMBL6483435 | 0.91 | TACR1 (0.79) | TACR1KCNH2 | |
| SCHEMBL6485381 | 0.91 | TACR1 (0.79) | TACR1KCNH2 | |
| SCHEMBL6494748 | 0.90 | TACR1 (0.75) | TACR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953792-B2 | Cyclohexyl derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-20030225059-A1 | Cyclohexyl derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-04 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | TACR1 1180/4885KCNH2 2908/4885OPRL1 281/4885 |
| US-20030225059-A1 | Cyclohexyl derivatives and their use as therapeutic agents | CNR2, CNR1, HRH2 | TACR1 389/4885KCNH2 211/4885OPRL1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.